Leucine-rich repeat kinase 2 (LRRK2) iRNA pharmaceutical compositions and methods of use thereof

The present disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions that target a leucine rich repeat kinase 2 (LRRK2) gene, as well as methods of using such dsRNAi agents and compositions to inhibit expression of an LRRK2 gene and methods of treating subjects having...

Full description

Saved in:
Bibliographic Details
Main Authors SCHLEGEL MARK K, DANG LY THI THANH, BARRY JEFFREY, CASTORENO, ANDREA, MCININCH JAMES D, STRYKOS, MICHAEL, NGUYEN, TRUC MINH, LEBLANC STEPHAN
Format Patent
LanguageChinese
English
Published 13.02.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions that target a leucine rich repeat kinase 2 (LRRK2) gene, as well as methods of using such dsRNAi agents and compositions to inhibit expression of an LRRK2 gene and methods of treating subjects having an LRRK2 related disease or disorder, such as Parkinson's disease. 本公开涉及靶向富含亮氨酸的重复激酶2(LRRK2)基因的双链核糖核酸(dsRNAi)药剂和组合物，以及使用此类dsRNAi药剂和组合物抑制LRRK2基因的表达的方法和治疗患有LRRK2相关疾病或病症，例如帕金森氏病(Parkinson's disease)的受试者的方法。
Bibliography:Application Number: CN202280045656